VERAXA Biotech AG (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (ADC) program beyond the initial discovery phase, following the completion of its collaboration with OmniAb. The company now plans to engineer the final candidate using its proprietary antibody-engineering, linker, and conjugation technologies, and to conduct in vitro and in vivo preclinical studies, according to a recent announcement.
VXA-222 employs an “AND-gate” design intended to recognize two tumor-associated antigens simultaneously, potentially increasing selectivity for cancer cells. This approach could lead to more precise targeting of tumors while sparing healthy tissue, a key goal in oncology drug development. VERAXA continues to develop a broader oncology pipeline spanning ADCs, T-cell engagers, and other engineered antibody formats.
The company has also filed its first patents covering its BiTAC-TCE and BiTAC-ADC platforms and related payload, click-chemistry, and conjugation technologies. These filings add to an intellectual-property portfolio that includes more than 50 granted patents across 26 families in 14 countries, underscoring VERAXA’s commitment to protecting its innovative technologies.
For investors, the progression of VXA-222 and the expansion of VERAXA’s patent estate signal tangible progress in a competitive field. The market for antibody-based therapeutics is growing, and companies that can demonstrate differentiated technology platforms may attract partnership or licensing interest. The news comes as VERAXA continues to build its presence in the biotech sector, with regular updates available through its newsroom at https://nnw.fm/VRXA and https://ibn.fm/VRXA.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, guided by rigorous quality-by-design principles. For more information, visit www.VERAXA.com.
The announcement was disseminated through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution to millions of followers, among other corporate communications solutions.
For the biotech industry, VERAXA’s advancement of VXA-222 highlights the ongoing trend toward more sophisticated antibody-drug conjugates that aim to improve efficacy and safety. If successful, such therapies could offer new options for patients with hard-to-treat cancers. The company’s patent filings also reflect the importance of intellectual property in securing a competitive edge in the rapidly evolving field of immuno-oncology.
As VERAXA moves VXA-222 into the next stage, stakeholders will be watching for preclinical data that could validate the AND-gate approach and support future clinical development. The company’s ability to execute on its pipeline and translate its scientific foundation into viable therapeutics will be key to its long-term success.
